Radiation Induced Upregulation of DNA Sensing Pathways is Cell-Type Dependent and Can Mediate the Off-Target Effects.

DNA sensors abscopal effects bystander effect immunostimulation irradiation

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
13 Nov 2020
Historique:
received: 03 10 2020
revised: 07 11 2020
accepted: 11 11 2020
entrez: 18 11 2020
pubmed: 19 11 2020
medline: 19 11 2020
Statut: epublish

Résumé

Irradiation of tumors generates danger signals and inflammatory cytokines that promote the off-target bystander and abscopal effects, evident especially when radiotherapy is administered in combination with the immune checkpoint inhibitors (ICI). The underlying mechanisms are not fully understood; however, cGAS-STING pathway was recognized as the main mediator. In our study, we demonstrate by immunofluorescent staining that tumor cells as well as macrophages, cell types abundant in the tumor microenvironmeent (TME) accumulate DNA in their cytosol soon after irradiation. This accumulation activated several distinct DNA sensing pathways, most prominently activated DNA sensors being DDX60, DAI, and p204 in tumor cells and DDX60, DAI, p204, and RIG-I in macrophages as determined by PCR and immunofluorescence imaging studies. This was accompanied by increased expression of cytokines evaluated by flow cytometry, TNFα, and IFNβ in tumor cells and IL1β and IFNβ in macrophages, which can alter the TME and mediate off-target effects (bystander or abscopal effects). These results give insight into the mechanisms involved in the stimulation of antitumor immunity by radiation.

Identifiants

pubmed: 33202881
pii: cancers12113365
doi: 10.3390/cancers12113365
pmc: PMC7696780
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : Z3-8204, P3-0003, BI-US/18-20-027
Organisme : NCI NIH HHS
ID : R01CA196796
Pays : United States

Références

Nat Immunol. 2010 Nov;11(11):997-1004
pubmed: 20890285
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Cancer Res. 2007 Apr 15;67(8):3845-52
pubmed: 17440099
Oncotarget. 2018 Apr 10;9(27):19368-19378
pubmed: 29721209
J Clin Invest. 2019 Oct 1;129(10):4224-4238
pubmed: 31483286
Biomed J. 2017 Aug;40(4):200-211
pubmed: 28918908
JAMA Oncol. 2015 Dec;1(9):1325-32
pubmed: 26270858
Cell Rep. 2015 May 26;11(8):1193-207
pubmed: 25981042
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Cancer Res. 1992 Nov 15;52(22):6394-6
pubmed: 1423287
Nature. 2008 Oct 2;455(7213):674-8
pubmed: 18724357
Cell Rep. 2015 Apr 21;11(3):460-73
pubmed: 25865892
Cancer Cell. 2018 Sep 10;34(3):361-378
pubmed: 30216189
J Mol Biol. 2020 Jan 17;432(2):552-568
pubmed: 31786265
Nature. 2007 Jul 26;448(7152):501-5
pubmed: 17618271
Br J Radiol. 2020 May 1;93(1109):20200042
pubmed: 32101479
Mol Cell Biol. 2011 Sep;31(18):3802-19
pubmed: 21791617
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17870-5
pubmed: 19805092
J Immunol. 2014 Jan 1;192(1):492-502
pubmed: 24307739
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
J Immunol. 2018 Apr 15;200(8):2748-2756
pubmed: 29540580
Cell Cycle. 2019 Aug;18(16):1830-1848
pubmed: 31260383
Nature. 2009 Mar 26;458(7237):514-8
pubmed: 19158675
J Hematol Oncol. 2018 Aug 16;11(1):104
pubmed: 30115069
Cancer Sci. 2009 Feb;100(2):303-9
pubmed: 19200259
Radiat Res. 2019 Dec;192(6):668-679
pubmed: 31618121
Oncogene. 2003 Oct 13;22(45):7050-7
pubmed: 14557810
Nucleic Acids Res. 2019 Nov 4;47(19):10235-10246
pubmed: 31495892
Sci Rep. 2019 Jun 24;9(1):9103
pubmed: 31235776
Nat Immunol. 2009 Oct;10(10):1065-72
pubmed: 19609254
Nat Immunol. 2011 Sep 20;12(10):929-30
pubmed: 21934672
Cancer Treat Res. 2020;180:281-296
pubmed: 32215874
Cell. 2009 Aug 7;138(3):576-91
pubmed: 19631370
Microsc Res Tech. 2000 Aug 1;50(3):184-95
pubmed: 10891884
Oncotarget. 2017 Jul 25;8(41):71249-71284
pubmed: 29050360
Cancer Lett. 2015 Jan 1;356(1):34-42
pubmed: 24333869

Auteurs

Tanja Jesenko (T)

Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.

Masa Bosnjak (M)

Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.

Bostjan Markelc (B)

Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.
Faculty of Health Sciences, University of Ljubljana, Zdravstvena pot 5, 1000 Ljubljana, Slovenia.

Gregor Sersa (G)

Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.
Faculty of Health Sciences, University of Ljubljana, Zdravstvena pot 5, 1000 Ljubljana, Slovenia.

Katarina Znidar (K)

Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.

Loree Heller (L)

Department of Medical Engineering, University of South Florida, 4202 E Fowler Avenue, Tampa, FL 33620, USA.

Maja Cemazar (M)

Department of Experimental Oncology, Institute of Oncology Ljubljana, Zaloska cesta 2, 1000 Ljubljana, Slovenia.
Faculty of Health Sciences, University of Primorska, Polje 42, 6310 Izola, Slovenia.

Classifications MeSH